IL17RA and neoplasm: Collectively, these data suggest that Mifamurtide, switching macrophage polarization towards a TAM-like intermediate M1/M2 phenotype and reducing IL-17R levels and STAT3 activation, may inhibit the cellular proliferation and induce the tumor cell differentiation.